Aurora, ILLINOIS31 Active Studies

Myalgic Encephalomyelitis Clinical Trials in Aurora, ILLINOIS

Find 31 actively recruiting myalgic encephalomyelitis clinical trials in Aurora, ILLINOIS. Connect with local research sites and explore new treatment options.

31
Active Trials
23
Sponsors
7,396
Enrolling

Recruiting Myalgic Encephalomyelitis Studies in Aurora

RecruitingAurora, ILLINOISNCT06097728

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinu...

825 participants
AstraZeneca
View Study Details
RecruitingAurora, ILLINOISNCT04262466

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Brenetafusp (IMC-F106C) is an immune-mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen PRAME. This is a fi...

727 participants
Immunocore Ltd
View Study Details
RecruitingAurora, ILLINOISNCT06112314

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)

This is a phase 3, randomized, controlled study of brenetafusp (IMC-F106C) plus nivolumab compared to standard nivolumab regimens in HLA-A\*02:01-positive participants with previously untreated advanc...

680 participants
Immunocore Ltd
View Study Details
RecruitingAurora, ILLINOISNCT05727904

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab al...

670 participants
Iovance Biotherapeutics, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT06486441

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemot...

640 participants
Gilead Sciences
View Study Details
RecruitingAurora, ILLINOISNCT05987332

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

This is a Phase 2/3, multi-arm, multi-stage, open-label study of human leukocyte antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive eit...

420 participants
IDEAYA Biosciences
View Study Details
RecruitingAurora, ILLINOISNCT05640999

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enroll...

393 participants
Canadian Cancer Trials Group
View Study Details
RecruitingAurora, ILLINOISNCT06719141

A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)

This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and...

320 participants
Longboard Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT06375811

Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp

A Phase 3 clinical trial of oral GnRH antagonist pre-treatment for women with endometriosis who are undergoing IVF, with a primary outcome of live birth rate. The investigators' central hypothesis is ...

297 participants
Yale University
View Study Details
RecruitingAurora, ILLINOISNCT03897881

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants w...

267 participants
ModernaTX, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT03955445

Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of iptacopan in subjects with C3 glomerulopathy or idiopathic immune-complex-membranoproliferative glo...

225 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT06914609

REVEAL: A Phase 3 Study of ION582 in Angelman Syndrome

The purpose of this study is to evaluate the efficacy and safety of ION582 in children and adults with Angelman syndrome caused by a deletion or mutation of the UBE3A gene....

210 participants
Ionis Pharmaceuticals, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT06840496

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatme...

210 participants
Biomed Industries, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT06660394

A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)

This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and a...

160 participants
Longboard Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT05136196

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may hav...

150 participants
National Cancer Institute (NCI)
View Study Details
RecruitingAurora, ILLINOISNCT06872125

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

The purpose of the study is to evaluate the efficacy, safety, and tolerability of zorevunersen in Patients with Dravet syndrome....

150 participants
Stoke Therapeutics, Inc
View Study Details
RecruitingAurora, ILLINOISNCT06624644

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

The goal of this clinical trial is to understand if a new drug called LNS8801 can safely treat patients with melanoma. The primary question to be answered is what is the average length of time during ...

135 participants
Linnaeus Therapeutics, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT06366464

A Study of Pitolisant in Patients With Prader-Willi Syndrome

This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The ...

134 participants
Harmony Biosciences Management, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT05755386

Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN

This study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in idiopathic immune complex media...

106 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT06144645

A Clinical Evaluation of Non-Invasive Vagus Nerve Stimulation for Temper Outbursts in People With PWS

The goal of the VNS4PWS clinical study is to test the efficacy, safety, and acceptability of transcutaneous vagus nerve stimulation (tVNS) treatment in people with PWS....

102 participants
Foundation for Prader-Willi Research
View Study Details
RecruitingAurora, ILLINOISNCT04817618

Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.

The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, r...

98 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT06196203

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed hig...

90 participants
Akeso
View Study Details
RecruitingAurora, ILLINOISNCT05127226

HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome

The purpose of this study is to evaluate the safety and tolerability of ascending doses of ION582 administered intrathecally in participants with Angelman syndrome....

70 participants
Ionis Pharmaceuticals, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT05662228

Therapies for Down Syndrome Regression Disorder

Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagn...

66 participants
University of Colorado, Denver
View Study Details
RecruitingAurora, ILLINOISNCT03949855

Belimumab With Rituximab for Primary Membranous Nephropathy

The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituxim...

58 participants
National Institute of Allergy and Infectious Diseases (NIAID)
View Study Details
RecruitingAurora, ILLINOISNCT05947500

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in p...

50 participants
National Cancer Institute (NCI)
View Study Details
RecruitingAurora, ILLINOISNCT06430385

ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)

The primary purpose of this study is to evaluate the safety and tolerability of ION440....

48 participants
Ionis Pharmaceuticals, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT06402123

A Phase 2b Study of Zagociguat in Patients With MELAS

PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administere...

44 participants
Tisento Therapeutics
View Study Details
RecruitingAurora, ILLINOISNCT06588491

KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD-19 CAR T) Therapy, in Subject With Treatment Refractory Stiff Person Syndrome

A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects With Treatment Refractory Stiff Person Syndrome...

25 participants
Kyverna Therapeutics
View Study Details
RecruitingAurora, ILLINOISNCT05898620

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

This study will evaluate the safety profile of the investigational gene therapy, NGN-401, in females with typical Rett syndrome....

14 participants
Neurogene Inc.
View Study Details
RecruitingAurora, ILLINOISNCT06598449

Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age

Dravet syndrome is a genetic epilepsy associated with pathogenic variants in SCN1A that codes for Nav1.1, a protein necessary for sodium channels. Children with Dravet syndrome classically present in ...

12 participants
University of Colorado, Denver
View Study Details

About Myalgic Encephalomyelitis Clinical Trials in Aurora

Myalgic encephalomyelitis (ME/CFS) is a complex, chronic illness characterized by profound fatigue, post-exertional malaise, cognitive impairment, and sleep dysfunction. It affects millions worldwide and has no definitive diagnostic test or cure. Research is exploring immune, metabolic, and neurological mechanisms.

There are currently 31 myalgic encephalomyelitis clinical trials recruiting participants in Aurora, ILLINOIS. These studies are seeking a combined 7,396 participants. Research is being sponsored by AstraZeneca, Immunocore Ltd, Iovance Biotherapeutics, Inc. and 20 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myalgic Encephalomyelitis Clinical Trials in Aurora — FAQ

Are there myalgic encephalomyelitis clinical trials in Aurora?

Yes, there are 31 myalgic encephalomyelitis clinical trials currently recruiting in Aurora, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What myalgic encephalomyelitis treatments are being tested?

The 31 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for myalgic encephalomyelitis.

Data updated March 2, 2026 from ClinicalTrials.gov